Beauty and Aesthetics Giant Loses $300 Million in Market Value Due to Conservative Earnings Guidance

Shares of Glaukos Corporation (GKOS) tumbled more than 5% intraday on the New York Stock Exchange today, erasing roughly $300 million in market capitalization—about ₩400 billion. Analysts say the slide reflects investor disappointment after the company’s SEC filing yesterday revealed preliminary net sales for Q4 2025 and the full 2025 fiscal year that were more conservative than the elevated expectations built up in recent weeks. Trading volume also spiked as profit-taking accelerated.

In its January 13 Form 8-K, Glaukos proactively issued guidance by disclosing its preliminary net sales for both Q4 2025 and the full fiscal year, alongside an updated investor presentation. Market observers interpret this as a strategic bid to recalibrate expectations ahead of the formal earnings release.

Meanwhile, Glaukos continues to invest in long-term growth. Last year, it broke ground on an R&D and manufacturing facility in Huntsville, Alabama, at a cost of about $80 million (roughly ₩100 billion). Slated for completion in 2030, the plant will serve as a key production hub to support its expanding glaucoma, corneal, and retinal therapy portfolio.

Headquartered in Aliso Viejo, California, Glaukos is a specialist ophthalmology pharmaceutical and medical device company. After pioneering the first commercial micro-invasive glaucoma surgery (MIGS) device, the company has driven growth with its “dropless” platform—featuring sustained-release glaucoma implants and corneal cross-linking treatments. Despite the recent pullback, analysts maintain that the company’s mid- to long-term growth story—underpinned by an aging population and rising chronic eye disease incidence—remains intact.